Evolution of the microbiota {#s1}
===========================

Bacteria arose about 3.8 billion years ago,[@R1] and the eukaryotic lineage, which includes humans, arose after the oxygenation of earth's atmosphere 2.2--2.4 billion years ago.[@R2] Together with archaea, protists and fungi, bacteria remained free-living single cells although some became host-associated. Thus, an animal holobiont (the animal host and its evolved microbial communities)[@R3] spans the phylogenetic tree: the animal host, plus its associated microbiota such as bacteria, archaea, fungi, protists, helminths and viruses ([figure 1](#F1){ref-type="fig"}). The collective genome content of microbiota or the microbial metagenome was coined the microbiome,[@R4] although microbiome and microbiota are currently used interchangeably.

![Evolution of the holobiont and vertical transmission through human generations.](gutjnl-2018-317503f01){#F1}

By coevolving with the host, the microbiome has shaped phenotypes in our ancestral lineages. The congruence of the phylogenetic trees of intestinal bacterial microbiota and primates[@R5] demonstrates host-microbiota coevolution and implies within-species transmission of microbes across generations. Through the process of natural selection, mutations lead to evolutionary adaptations to environmental conditions and increased fitness in these environments. Human environments have changed dramatically during human evolution, and dietary changes and exposures to famine have been major selective pressures. While there is evidence of adaptive survival traits to starvation on the human genome,[@R6] human microbiome adaptations that offer energy-sparing traits for the human host remain unknown. Abrupt changes in environmental conditions can lead to mal-adaptations (adaptations that were beneficial when first took place, but not anymore under new environmental conditions). Today, modernisation and urbanisation pose exactly this challenge to human health.

Together with their microbionts (microbiota members), hosts evolved an immune system, which prevents microbial colonisation in the topological interior of the body. Host immune systems evolved complex mechanisms to identify and destroy invading microbes, whether they are microbionts or primary pathogens that cross into forbidden territories. Immune molecules evolved more than 500 million years ago, in choanoflagellates, unicellular progenitors of metazoans,[@R7] and there is growing evidence that the innate immune system---antimicrobial peptides and repertoire of pattern recognition receptors---evolved in response to the need for controlling the epithelium-colonising microbiota.[@R8]

The human immune system restricts microbiota to their natural niches in the body 'exterior' and invaginations: epithelia that cover the body (such as skin and mucosa) and the gut, which, strictly speaking, is a hollow tube that traverses the body with the influx of external materials (diet). Thus, the microbiota occupies the interface between our bodies and the exterior, and interactions with the environment (including diet, sun-light, bathing, cosmetics) cross this interface. The microbiota is at the same time self and non-self: it is part of our biology, but consists of fast-evolving entities that respond rapidly on physiological, ecological and evolutionary timescales to external perturbations in ways that affect our phenotypes ([figure 1](#F1){ref-type="fig"}). The gut microbiota have been shown to impact diverse physiological processes ranging from adiposity/obesity, to energy metabolism, blood pressure control, glucose homeostasis, clotting risks or even behaviour. In each case, there are mechanistic ties between gut microbes, metabolites they generate and host receptors and phenotypic responses. Evolutionary considerations are crucial to understanding the nature of microbial-host interactions, perturbations and health consequences and will ultimately need to be understood and exploited in order to prevent and treat 'modern' diseases.

Development and the microbiota: from fertilisation to birth {#s2}
===========================================================

In some insects, bacteria colonise egg capsules during mating, and the individual is colonised before hatching.[@R9] In mammals, fertilisation occurs in an immune-protected organ, the uterus. However, immune protection means lack of colonisation, but not necessarily sterility at all times. Indeed, it seems possible that some bacterial cells of the uterine cervix[@R10] may enter with the sperm during fertilisation and reach the egg at the time of fertilisation, implantation or early embryonic development. Regardless, immunity appears to preclude the establishment of a microbial community in immune-protected organs. Uterus, placenta, fetus as well as blood appear void of a microbiota, although they may contain bacterial DNA or even some isolated live bacteria. There is a current controversy about whether the presence of bacterial DNA contradicts the notion of sterility, but the presence of circulating bacterial DNA, such in the blood[@R11] or placenta,[@R12] or even sporadic presence of an alive intruder bacteria does not demonstrate a living blood microbiota and does not challenge the current paradigm of sterility in immune-protected organs. There might be a transitory 'mini-sepsis' when live cells enter the blood after injuries, microabrasions or mucosal 'leaking'[@R13]---including transient bacteraemia due to tooth-brushing[@R14]---, but in healthy individuals, the intruders are cleared by phagocytic cells rather than colonising and assembling microbial communities. Fetal development is an important period for the reproduction of placental species, and gestational infection and inflammation reduce fecundity and increase the risk of spontaneous preterm birth[@R15] The concept of sterile fetal development remains, and little is known about mechanisms and functions of transplacental trafficking of free nucleic acids.

The maternal microbiota may exert an indirect effect on the fetus via maternal factors such as maternal immune responses or microbial metabolites that cross the placenta[@R17] or more indirectly via factors that may mediate epigenetic programming in the fetus, such as diet,[@R20] stress[@R21] or neuroendocrine exposure,[@R22] which also affect the maternal microbiota. The gut[@R25] and vaginal[@R26] maternal microbiota change with gestation, and whether or not these changes have adaptive value for the mother or baby is still unknown. It has been suggested that they allow the fetus to derive energy from the mother's blood, more efficiently,[@R25] or that butyrate-producing bacteria may sustain gut epithelial functions and promote immune tolerance in the mother.[@R27]

Labour and birth represent the first major exposure to a complex microbiota and is the primordial mechanism for intergenerational microbiota transfer in mammals. Ancestral vertebrates (birds, reptiles, finned fishes) and, exceptionally among mammals, the Monotremes, lay eggs through a single canal---the cloaca---shared for excretion and reproduction. Placental mammals evolved separate canals for reproduction (vagina), excretion of faeces (anus) and urine (urethra), and the birth canal is always adjacent to the rectum (but not the urethra), providing an efficient mechanism for intergenerational transmission of both vaginal and gut microbes. Rupture of the chorioamniotic membrane allows exposure of the baby to the maternal vaginal and perineal faecal microbes. Indeed, prolonged labour poses a risk of infection by opportunistic microbionts.[@R28] Infants are naturally born with their skin and mouth covered by maternal inocula and have swallowed these microbes,[@R29] supported by the observation of both DNA[@R31] and live bacteria[@R31] in the meconium. Thus, we inherit the primordial microbiota from our mothers, grandmothers and further on the matrilineal line, with microbial vertical transmission extending back to earlier ancestors[@R32] ([box 1](#B1){ref-type="boxed-text"}). Whether the primordial inoculum contains most microbes that will be nurtured by the child, and which maternal strains colonise which parts of the baby's body and their functions, the paternal and sibling contribution along with the infant's microbial diversity[@R33] and the extent to which modern practices reduce intergenerational transmission, are still not completely understood. C-section as intrapartum antibiotics during vaginal delivery alter bacterial colonisation in the neonates.[@R34] Box 1Highlights of the holobiont evolutionEvolution of all complex life forms has occurred in associations with bacteria, the first forms of life on earth.The human body carries representatives of all branches of the tree of life (Animalia-Homo sapiens, and protozoa, fungi, archaea, bacteria conforming the microbiota).The microbiota has been transferred throughout generations of humans, with the matrilineal line transferring the primordial birth microbiota.The vertical human transmission has led to conservation of a phylogenetic signal in human microbiota communities.

Postnatal development of the microbiota {#s3}
=======================================

By definition, placental mammals develop in a placenta, are born through the maternal vagina and drink maternal milk during the initial developmental window during which remarkable changes occur. Animals can develop without microbiota, as shown by the existence of germ-free mice, rats, chickens and pigs, but they have abnormal phenotypes and the microbiota is believed to be required for normal development. Pioneer neonatal bacteria prime the development of the microbiota, immune, metabolic, hormonal and nervous systems in the neonate.[@R35] Under natural conditions, the neonate and the microbiota develop in an orchestrated fashion under the nutritional, immunological, hormonal and prebiotic effect of maternal milk---a single food of complex biological formulation.[@R37] Bacteria acquired during labour include lactic acid bacteria that digest lactose, and others that use substrates that are indigestible for the babies (indigestible milk glycans known as  human milk  oligosaccharides, or HMOs),[@R38] with polymorphisms, such as in fucose transferase gene FUT2, associated with selective effects of HMOs on the infant microbiota composition,[@R40] which in turn can affect the susceptibility to immune diseases later in life.[@R41] Milk also includes urea and oxalate, two end-products of human metabolism. Why would nature include such indigestible molecules in the diet of young mammals? There are beneficial microbes that can use these molecules such as carbon, nitrogen or other energy sources. The types of glycans found in breast milk can shape the infant gut microbiota and the microbial composition of breast milk, specifically of *Bifidobacterium* species.[@R42] The degree of development of the sensory and motor capabilities of the brain in neonates during strict lactation is remarkable. Ultimately, understanding this period, the functions of milk glycans and other molecules, and the microbes they select, will be critical to understand human development.

Other ways in which the microbiome has been related to development include the synthesis of vitamins during postnatal development. There is poor vitamin K diffusion through the placental barrier,[@R43] thus neonates are born with low vitamin K levels.[@R44] Later, intestinal bacteria will provide K2 or menaquinone, and older children will consume it from vegetables in the form of phylloquinone. Vitamin K is necessary to synthesise functional forms of coagulation factors II, VII, IX, and X in the liver.[@R45] Often clinicians consider that neonates are vitamin K-deficient, but again, from the evolutionary perspective, we need to ask why has this trait been selected during our evolution. Similarly, it is thought that babies that are exclusively breastfed may become deficient in vitamin B12 due to the lack of solid foods rich in this vitamin.[@R46] Does it hold adaptive value or is it a maladaptation? The answer to this question is important, since clinical interpretations lead to public health measures that affect millions of infants, such as the recommended vitamin K boost to all neonates.[@R47] We need to understand our biology first, before we define pathologic scenarios and intervene. Much research is needed to identify adaptations that we must respect, and then define the maladaptations that need to be addressed.

The microbiota development trajectory from birth follows dynamic changes. Immediately after birth, there seems to be a decrease in gut alpha diversity[@R48] probably reflecting the selective pressure of the substrate constraints of milk, and by 1 week of age, the gut microbiota is already very similar to that in a month-old baby.[@R50] Infants develop during the first 6 months under the selective pressure of milk shaping the gut microbial communities, whose metabolites promote peripheral regulatory T-cell generation.[@R51] Bacteria given to germ-free mice induce germinal centres (lymphoid cells) to produce IgA^+^ B cells.[@R52] Bacterial molecules also induce mucosa-associated lymphoid tissue of the intestine, via Toll-like receptors, and shape the intestinal Th-cell mediated immunity.[@R53] Thus, antigen-driven priming/activation, polarisation and expansion of *naïve* T cells yield Th1 and/or Th17 effector cells,[@R54] which enter the systemic circulation and home to the gut to help destroy the invading pathogens.[@R55] GF animals consistently exhibit impaired development of Peyer's patches,[@R56] have reduced numbers of T-helper (Th)1 and Th17 cells, with the intestinal T-cell immune response primarily controlled by Th2 cells.[@R57] Importantly, the imbalances in Th-cell responses in GF mice can be reversed by restoring the microbiota.[@R52] Th17/Tregs are involved in tolerance of and is induced by microbionts such as *H. pylori* and commensal *Clostridia*-related bacteria.[@R58] Perturbations that reduce transmission and early colonisation of human bacteria lead to reduced numbers of Th17 cells in the small intestine.[@R52] Environmental variables may also affect the microbiota, such as number of siblings (babies with siblings have increased gut *Bifidobacterium catenulatum*) and sex (girls having higher gut *B. fragilis* and *Lactobacillus* spp. than boys).[@R60] Finally, evidence suggests that longer duration of breastfeeding is associated with decrease in risk of overweight.[@R61]

In the large intestine and colon, bacteria can either colonise the epithelial mucosa, digesta particles or live free in suspension in the liquid phase. Particles and liquid colonisation is dictated in part by transit time in the intestine. After strict lactation ends, dentition begins, and the GI system of the baby has matured to handle dietary solids that reach the postabsorptive sites and bring new substrates. These solids change the conditions in the hindgut, selecting for bacterial populations with relevant metabolic activities and the microbial diversity of the intestine increases steadily until at least age 3 years.[@R62] This increase in diversity may reflect the increased chemical diversity of a complex diet and the gut and immune maturation of the host.

The new solid diet has components refractory to proximal intestinal digestion, such as some starches and cell wall polysaccharides of plant origin, which are fermented by bacteria in the large intestine. The products, short chain fatty acids, have modulatory roles in host metabolism and immunity. Butyrate has beneficial effects, being energy source for colonocytes, maintaining epithelial integrity in the gut,[@R63] supporting Treg differentiation and driving anti-inflammatory responses,[@R51] as shown with bacterial butyrate producers, such as *Faecalibacterium prausnitzii,*,[@R64] or by direct supplementation of butyrate to mice.[@R65] Propionate also potentiates de novo Treg-cell generation in the periphery.[@R51] Butyrate and acetate regulate satiety,[@R66] with acetate being obesogenic.[@R67] High *Bacteroides* and low acetogens and methanogens have been associated with reduced weight gain.[@R68]

The convergence in metabolic products produced by the repertoire of microbes in the gut ecosystem is an example of functional redundancy. Functional redundancy is a recognised trait of the microbiota in human adults,[@R69] leading to high interindividual variability and, importantly, increasing resilience of the ecosystem. Redundancy probably increases with age, at least during the first 3 years of life, when diversity is gained,[@R62] but this phenomenon is still poorly understood. We are depleting our ancestral microbiome diversity and its functional repertoire, and this results in compromising redundancy, with detrimental effects on the resilience that governs complex metabolic interactions.

Modern disruptors of the microbiota and modern diseases {#s4}
=======================================================

Industrial urban societies have dramatically changed human lifestyle in relation to traditional societies, and the world is becoming increasingly urban. The changes are complex, including housing, urban plan, human density, home architecture, technologic isolation of houses from the environment, ventilation, diet, clothing, exercise, personal care products and medicines. Understanding what changes with urbanisation requires a multidisciplinary approach and is important because sudden environmental changes may lead to maladaptations. Urbanisation is indeed associated with increased risks of immune and metabolic diseases, including obesity, T1D, behavioural disorders, IBD and asthma, all of which have been increasing in recent decades,[@R70] and with reduced gut microbiota diversity.[@R62] Although human genetics affects host development as well as the structure of the microbiota,[@R75] the effect of environmental factors on the microbiota is known to be substantial. Practices that significantly impair transmission and colonisation of bacteria early in life are abundant in modern societies, and we have learnt from ecological studies that compounded impacts or removal of high competitive populations reduces alpha diversity, while removal of more cooperative bacteria (or of redundant bacteria) has a smaller effect on diversity. Selective pressures that are shaping microbiome characteristics within high-income countries may include prenatal and postnatal antibiotics exposure, dietary antimicrobials, toothpaste, soaps and perhaps even consumption of chlorinated water. The direction of changes of the microbial ecosystem after perturbations depends on the ecosystem and does not always imply reduction of diversity. For example, perturbations in the microbiota of the vagina and of the stomach, which are naturally of low alpha diversity, increase richness and evenness.

There are connections between increased disease risks and microbiota. Obesity risk has been epidemiologically associated with C-section birthing and early antibiotic exposure.[@R73] Evidence of obesity causation has been shown in mice,[@R76] with population-scale studies leading to identification of bacteria that when transplanted to mice had physiological effect on body mass.[@R77]

Early life microbiota functions are likely to be key in understanding the aetiology of chronic immune diseases of urban societies and where potential for their prevention resides. In the gut, reduced microbiota diversity is consistent with reduction in resilience---the capacity to bounce back after perturbations---and in resistance---to pathogens. In clean urban settings, where sanitation and vaccines diminish colonisation by pathogens, reduction in resistance might not be as important as it was as in ancestral human societies exposed to more infectious challenges). However, with the compounded effects of perturbations exerted by the antimicrobial practices of modern life, loss of resilience might be important. Moreover, much research is needed to understand the role of gut microbiota in vaccine and immunisation efficacy, the timing of vaccines provided to infants and children and the impact of not just antibiotics, but other drugs[@R78] on microbial community structure.

Gestational use of antibiotics affects microbiota colonisation in the infants.[@R79] In the USA, about one in two women is prescribed an antibiotic during pregnancy or at term, and beta-lactams, vancomycin, nitrofurantoin, metronidazole, clindamycin and fosfomycin are generally considered safe. However, antibiotics given 4--5 days before birth in mice changed proportions in gut bacteria in the litters and affected lung lymphoid cell development.[@R80] Lack of maternal microbiota exposure at birth, as happens in the C-section born, leads to alterations in the microbiota of babies[@R30] and in fatty acid and bile acid metabolism.[@R60] Formula also alters the baby microbiota[@R81] and the modern practice by working mothers, of bottle feeding breast milk -rather than directly breastfeeding- may also have effects. This practice involves refrigerating or freezing - thawing and reheating breast milk, and reduces maternal-baby contact. How this might affect microbial transmission has not been studied. Thus, the compounded effect of prenatal, perinatal and postnatal antibiotics, C-section birth, formula feeding, reduced skin to skin and mouth-breast contact between babies and mothers, extensive bathing of the neonate and other hospital interventions and a built environment isolated from the natural environment, might all count and be cumulative in their effects.

More information is needed to understand the functions of the early microbiota and its relation with later health conditions. Cohort studies are currently ongoing; ClinicalTrials.org shows 17 longitudinal clinical trials with interventions and 18 without interventions, being performed in infants ([table 1](#T1){ref-type="table"}).

###### 

Clinical studies on the development and restoration of the infant microbiome

  Intervention/Follow-up up without intervention   ClinicalTrials.gov Identifier                                                                                                                                                                                                              Participant enrolment
  ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------
  Antibiotics at birth                             NCT02477423                                                                                                                                                                                                                                80
  Antibiotics in preterm                           NCT02784821                                                                                                                                                                                                                                420
  At-birth restoration with vaginal fluids         NCT03298334                                                                                                                                                                                                                                800
  Diet supplementation---eggs                      NCT03385252                                                                                                                                                                                                                                662
  Diet supplementation---sweet potato vs pear      NCT03229863                                                                                                                                                                                                                                120
  Diet supplementation---Human milk fortifier      NCT03214822                                                                                                                                                                                                                                30
  Diet supplementation-maternal---Omega-3          NCT03297801                                                                                                                                                                                                                                109
  Diet supplementation---protein sources           NCT02142647                                                                                                                                                                                                                                40
  Human milk donor                                 NCT02573779                                                                                                                                                                                                                                125
  Probiotic/prebiotic supplemented formula         NCT03320837                                                                                                                                                                                                                                108
  Probiotics                                       NCT03388112                                                                                                                                                                                                                                30
  Probiotics *B. breve*                            NCT03219931                                                                                                                                                                                                                                320
  Probiotics in preterm                            NCT02197468                                                                                                                                                                                                                                60
  Probiotics in preterm                            NCT02695784                                                                                                                                                                                                                                40
  Rotavirus vaccine                                NCT03031743                                                                                                                                                                                                                                88
  Rotavirus vaccine                                NCT02220439                                                                                                                                                                                                                                76
  Skin-to-skin contact                             NCT03181269                                                                                                                                                                                                                                88
  Follow-up without intervention                   NCT03001167, NCT02121938, NCT03365583, NCT03236194, NCT01789268, NCT02778750, NCT02526004, NCT02843087, NCT03229967, NCT01661491, NCT03235635, NCT03296631, NCT03396198, NCT02836119, NCT03335202, NCT02061306, NCT03213275, NCT03373721   Variable

The interventions include important issues such as at birth exposure to vaginal fluids and skin-to-skin contact, dietary supplementation with probiotics, proteins, carbohydrates, fortified milk, antibiotics in preterm babies. Outcomes include microbiota development, bacteriophage populations during development, infant growth, urinary metabolites, immune profiles, incidence of infections, the development of infantile colic, celiac disease and bronchopulmonary dysplasia as well as sleep behaviour and neurodevelopment. Causation studies are difficult in humans, and normally involve longitudinal randomised clinical trials, which are expensive, and in the USA typically require an Investigational New Drug (IND) approval from the Food and Drug Administration (FDA), which adds costs, complexity and time to the studies. Certainly, more studies are needed to determine reproducibility, safety and benefits of early restorations to C-section-born babies, particularly in the context of randomised control studies addressing the risk of asthma, atopy and other relevant clinical endpoints.

Medicine is one of the great human creations, and its life-saving capability has driven the substantial increase in human lifespans. Medical interventions such as vaccines, antibiotics and surgery have contributed dramatically to improve life expectancy. For example, antibiotics treat major killers including diarrheal disease and pneumonia and C-sections save both infants and mothers, with formula nourishing and supplementing children that cannot be breastfed. However, these interventions come with costs that have been underestimated, with the consequent overuse and abuse. Such costs are only justified when the intervention is needed. Changes in practice will only arrest the current trend, and restoration efforts will be needed to decrease the intervention costs. Identifying the 'when' and 'what', the timing of interventions and the breadth of influence of specific microbial species and strains, is essential if we are to intervene effectively. Restoration efforts ought to be carefully considered, weighing risks and potential benefits. For example, restoration of the neonatal microbiota of C-section born neonates with maternal vaginal fluids[@R82] has raised concerns of infection risks to neonates posed to by vaginal exposure[@R83] (see also ACOG note in <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Vaginal-Seeding>), and although this exposure is natural and has been conserved over the millions of years of mammalian evolution, only solid scientific demonstration of health benefits will pave the road for the practice to become standard clinical practice. Restoration approaches are also promising to counteract the associations between altered microbiology in successfully treated childhood cancers and the consequent persistent increased risk of inflammatory diseases.[@R85]

Creating a synthetic human milk {#s4a}
-------------------------------

Research on prebiotic and probiotic functions of human maternal milk could lead to the design of synbiotic formulas that respect the developmental biology of the child and drive a healthy infant gut, although frankly, it will take years to produce a biologically appropriate synthetic human milk that includes the changing circadian and developmental levels of glycans (HMOs), hormones, cells and antibodies. We are far from being there, but the initial efforts have started with the Danish Biotech Glycom adding N- Acetyl-D-Neuraminic acid to formula.[@R86] Understanding the coevolution of milk glycans, the immune system and gut bacteria in infancy across mammals may provide a translational model for modulation of the gut microbiota.

Research on prebiotic and probiotic functions of human maternal milk could provide an important information base to design synbiotic formulas that respect the developmental biology of the child, to drive a healthy infant gut. We are far from being there, but the initial efforts have started with the Danish Biotech Glycom adding N- Acetyl-D-Neuraminic acid to formula,[@R86] but of course milk is far more than that and contains glycans (HMOs), hormones and antibodies. A recent oral synbiotic preparation of a *Lactobacillus plantarum* and fructooligosaccharide resulted in a reduction of neonatal sepsis in rural Indian newborns.[@R87] Understanding the coevolution of milk glycans, the immune system and gut bacteria in infancy across mammals may be critical in improving human health in infants and provides a translational model for modulation of the gut microbiota.

Restorations of mothers to hand out the next generation microbiota {#s4b}
------------------------------------------------------------------

The idea of freezing healthy stools and using them to restore after antibiotic treatment has not been implemented but seems ecologically plausible. Babies could have their predisease microbiota restored, and adults too, particularly women, who play a particularly important role in transmitting the human microbiota to the next generation. There is a need for services provided by companies, who allow families to regularly store the growing infant microbiota, for this purpose; being a self-transplant, it is not clear what will be required from regulatory agencies such as the FDA.

What is a healthy microbiome? {#s5}
=============================

Individuals differ enormously in the taxonomic content of their microbiota, and even the same person over time can appear dramatically different from their own prior representation. Functional redundancy makes the characterisation of the healthy microbiome extremely complex, because different taxonomic profiles can lead to ecosystems with similar behaviour. It is also unclear whether 'normal' in a human population implies healthy, because the health optimum might be context-dependent both at a population and at an individual level---is the average microbiome of lean 20-year-olds, half of whom will become chronically ill 70-year-olds, really healthy? Studies of healthy children in 10 locales in Asia showed substantial variation in the composition of the gut microbiota, yet there was a clear North-South pattern in terms of predominant taxa, likely related to different levels of socioeconomic modernisation and market integration.[@R88] Thus, we do not yet know what are the key features of healthy microbiomes, beyond the descriptive composition that characterises body sites: *Staphylococcus, Streptococcus, Actinomyces, Veillonella, Fusobacterium, Porphyromonas or Treponema* species in the oral cavity[@R89], with shared lifestyle, environment and genetic factors playing a role;[@R90] *Acinetobacter and Aeribacillus* in the ocular surface, *Pseudomonas* on the lid margin and conjunctiva;[@R91] Actinobacteria (Corynebacteriaceae and Propionibacteriaceae and Firmicutes---mostly Staphylococcaceae, Bacteroidetes and Proteobacteria in the skin,[@R92] lipophilic organisms such as *Propionibacterium* spp. and the fungus *Malassezia* spp. in areas of higher density of sebaceous glands (face or back),[@R93] Firmicutes and Bacteroidetes, including *Bacteroides, Prevotella*, *Ruminococcus, Bifidobacterium, Streptococcus, Enterobacteriaceae, Enterococcus, Lactobacillus*, the Verrucomicrobia *Akkermansia* and the archaeal *Methanobrevibacter smithii* in the mucosal surfaces of the gastrointestinal tract,[@R95] and *Lactobacillus* spp. in the women's genital tract.[@R101] The ubiquity of the 'core' dominant metabolisms[@R69] contrasts with the variability of niche-specific low abundant functions, many of which remain uncharacterised. A possible approach to the complexity of the human microbiome variability and disease risks is to obtain longitudinal data from multiple cohorts in global studies from which subjects developing any diseases throughout their lifespan are excluded, and only the healthy subjects (lacking a disease phenotype) are considered. In ecosystems like the gut, the extent of diversity is one proxy for health. Immigrants from developing countries lose diversity across human generations, as they develop westernised lifestyles and diseases.[@R106]

In children, we urgently need prospective studies that assess how well the microbiome matures across a population of healthy individuals, just as we normalise the maturation of height and weight in children and then compare those with disease states---essentially a growth curve for the developing microbiome. Just as for these physical attributes, knowledge of normal development allows abnormalities to be detected. Studies in humans using such approaches now indicate that it is possible to recognise the effects of disease states, for example,  malnutrition[@R107] and also the effects of perturbations, such as C-section or antibiotic exposures. Physicians have begun to use concepts of maturation in pathological states, such as in recipients of bone marrow transplantation or after faecal transplant to treat *C. difficile* infection to predict who might have a more successful outcome.

Focusing on functions, rather than taxa, may be important in addressing some research and clinical questions but may not be applicable to others, because each strain delivers a combination of functions, under multiple selection pressures and thus it is difficult to determine which components of the ecosystem can be manipulated without unintended consequences. Understanding the dynamics and effects of microbiome changes may be analogous to predicting the weather. We can see some general outlines that help us with the 3-day forecast, but as we attempt to forecast further out, the complexity of the system overwhelms the available tools. Because this is a young field, as knowledge grows and tools become more refined, our ability to classify and predict will correspondingly grow.

Future perspectives {#s5a}
-------------------

The human holobiont is progressively being understood, as the collective microbiome and host functions are better characterised in health and disease, and as we assess both correlation and causal relationships. Efforts to standardise specimen preparation[@R108] and analytical protocols and to increase the availability of the growing body of data[@R109] are increasing. These technical efforts as well as robust clinical studies will improve characterisation of the variation in the global human microbiomes, functions of redundancy, trajectories of development, effect of lifestyles, immigration,[@R106] disease biomarkers, all of which will establish the basis to understand the progression from health to disease and to efficiently discover new preventive interventions and therapies.
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